Warning on risks: Financial contracts for difference are complex instruments and are associated with a high risk of rapid financial losses due to leverage. On 72.29% of retail investor accounts, financial losses occur when trading financial contracts for difference with this provider. You should consider whether you understand how financial contracts for difference work, and whether you can afford to take the high risk of suffering financial losses. Please read the Risk Disclosures.
Market analysis and news
Get an overview of current market developments with regular analysis from our analysts. We offer a detailed view of key events, economic indicators and investment opportunities. Follow the development of the markets with us and make decisions based on data and experience.
With the rise of COVID-19, vaccine makers fought in the pharmaceutical battleground, to gain national trust for its vaccine effectiveness and safety. The outbreak of the coronavirus pandemic incentivized multiple companies to develop vaccines, including Novavax, Sputnik and GlaxoSmithKline (GSK), but generally speaking, four vaccine makers came out on top to mass produce COVID-19 immunization; Johnson & Johnson, Pfizer/BioNTech, Moderna and AstraZeneca. But, how are the vaccine victors performing lately, now that COVID-19 has hit the brakes?
It will soon be two years since the outbreak of the COVID-19 virus. Despite the development of new vaccines and the efforts of a global approach to vaccination, many are still wondering what the recovery of the global economy might look like and whether it can recover from a pandemic. However, its outlook does not look ideal yet. The International Monetary Fund (IMF) lowered its July forecast of global economic growth to 5.9 percent in 2021 in its October World Economic Outlook report, and the outlook for 2022 remains at the same level, namely 4.9 percent.
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic of Covid-19 vaccine and the need of vaccination has often been mentioned in the media. Even so, new vaccines are still being developed all around the world. They play a key role in treatment of the infected and pharmaceutical companies are fighting for development of the most effective drug. OZIOS has prepared a summary to introduce how companies are doing on the market.
During last year, Moderna stocks surpassed wider market and experienced record growth of 509% (to the date of 26th August 2021). The value exceeded total returns of the S&P 500 index reaching 28% (to the date of 26th August 2021). The pharmaceutical company recorded success last performed by Tesla Inc.
Latest analyses